Clinical Trials for Beta Haemolytic Streptococcal Infection
There is currently 1 ongoing clinical trial investigating prevention strategies for Beta Haemolytic Streptococcal Infection, specifically focusing on Group G and C Streptococcus infections in pregnant women. This trial is being conducted in Finland and is testing antibiotic prophylaxis during labor to prevent infections in mothers and newborns.
Clinical trial locations
Antibiotic Treatment with Clindamycin and Benzylpenicillin to Prevent Group G and C Streptococcal Infections in Pregnant Women
This clinical trial is investigating ways to prevent infections caused by Group G and C Streptococcus bacteria during and after childbirth. These bacteria can naturally live in the vaginal and rectal areas of some pregnant women without causing problems, but they can potentially lead to serious infections in both the mother and newborn during delivery.
Who can participate:
- Pregnant women between 35 and 38 weeks of pregnancy
- Women who have tested positive for carrying Group G or C Streptococcus bacteria in their vaginal-rectal area during routine screening (usually performed when testing for another common bacteria called GBS)
- Only female participants are eligible for this study
Who cannot participate:
- Women who are not pregnant
- Women who do not have Group G or C Streptococcus bacteria present in their vaginal-rectal area
- Women who are not in late pregnancy
- Men are not eligible for this study
What the trial involves:
The main goal of this study is to determine whether giving antibiotics during labor can effectively prevent infections in mothers and their newborns. The trial uses two antibiotics: Clindamycin and Benzylpenicillin, which are given through an injection or infusion directly into the vein during labor. These medications work by preventing bacteria from building their cell walls, which destroys the harmful bacteria.
Participants will be compared with others who receive a placebo (an inactive substance) to see if the antibiotics truly make a difference in preventing infections. The research team will monitor mothers for any signs of infection that might require antibiotic treatment for up to three months after delivery. They will also carefully watch the newborns for any health issues, including whether they need additional medical care or transfer to a neonatal intensive care unit.
The study follows participants through several stages: joining the study after positive test results, receiving antibiotics during labor, monitoring after childbirth for infection signs in the mother, evaluating the newborn’s health including any need for blood cultures or treatment, and recording the length of hospital stay for both mother and baby.
Investigational treatment:
The trial is testing antibiotic prophylaxis administered during labor. This preventive treatment aims to reduce the risk of Group G and C Streptococcus infections being passed from mother to baby during delivery and to prevent postpartum complications in the mother, such as fever and inflammation that could require medical attention.
Summary
Currently, there is one clinical trial actively recruiting pregnant women in Finland to study prevention strategies for Beta Haemolytic Streptococcal Infection. The trial specifically targets Group G and C Streptococcus bacteria, which can cause infections during and after childbirth. The study focuses on using antibiotic prophylaxis with Clindamycin and Benzylpenicillin during labor to protect both mothers and newborns from these bacterial infections. This research is particularly important as these bacteria can be present naturally in pregnant women without symptoms but may cause serious complications during delivery if not properly managed.